Overview

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

Status:
Recruiting

Trial end date:
2022-07-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability, PK and PD of BBP-671 in healthy volunteers and patients with Propionic Acidemia or Methylmalonic Acidemia.

Phase:

Phase 1

Details

Lead Sponsor:

CoA Therapeutics Inc.
CoA Therapeutics, Inc., a BridgeBio company